NCT03601520 (DL-SSc) is a clinical trial in Diffusion Limitation of Pulmonary Gas Exchange in Systemic Sclerosis, sponsored by IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.

Is NCT03601520 still recruiting?

NCT03601520 is currently completed. Last updated 27 July 2018.

Last reviewed 2018-07-27 · How we verify

NCT03601520: DL-SSc

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mechanisms of Pulmonary Diffusion Limitation in Systemic Sclerosis

Completed Last updated 27 July 2018

What this trial tests

trial in Diffusion Limitation of Pulmonary Gas Exchange in Systemic Sclerosis in 100 participants. Completed in 15 November 2017.

Timeline

1 March 2014

Primary endpoint
31 October 2017

15 November 2017

Quick facts

Lead sponsor	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Status	Completed
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 March 2014
Primary completion	31 October 2017
Estimated completion	15 November 2017

Conditions studied

Diffusion Limitation of Pulmonary Gas Exchange in Systemic Sclerosis — all drugs for Diffusion Limitation of Pulmonary Gas Exchange in Systemic Sclerosis →

Sponsor

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy — full company profile →

Who can join

Eligibility, any sex, with Diffusion Limitation of Pulmonary Gas Exchange in Systemic Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was designed to test the hypothesis that, irrespective of the degree of interstiaI lung disease and/or pulmonary arterial hypertension, the combined measurement of lung diffusing capacity for nitric oxide and carbon monoxide, might be useful to provide a mechanistic interpretation of changes of diffusion subcomponents in systemic sclerosis (SSc).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Value of lung diffusing capacity for nitric oxide in systemic sclerosis.
Barisione G, Garlaschi A, Occhipinti M, Baroffio M, et al · · 2019 · cited 8× · PMID 31264386 · DOI 10.14814/phy2.14149

Verify or expand the search:

Other IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy trials

Trials by the same sponsor.

NCT07091838 — Lung Diffusing Capacities Normality Thresholds in Pulmonary Fibrosis and Emphysema · completed
NCT05430503 — Long COVID and Post-exertional Pulmonary Diffusion · completed
NCT05998837 — GLUcose Transport and REnalPROtection in Chronic Kidney Disease · Phase 2, PHASE3 · completed
NCT04610554 — Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03601520 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Last refreshed: 27 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03601520.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing